Quantifying arrhythmic long QT effects of hydroxychloroquine and azithromycin with whole-heart optical mapping and simulations

BACKGROUND: In March 2020, hydroxychloroquine (HCQ) alone or combined with azithromycin (AZM) was authorized as a treatment for COVID-19 in many countries. The therapy proved ineffective with long QT and deadly cardiac arrhythmia risks, illustrating challenges to determine the new safety profile of...

Descripción completa

Detalles Bibliográficos
Autores principales: Uzelac, Ilija, Kaboudian, Abouzar, Iravanian, Shahriar, Siles-Paredes, Jimena G., Gumbart, James C., Ashikaga, Hiroshi, Bhatia, Neal, Gilmour, Robert F., Cherry, Elizabeth M., Fenton, Flavio H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Experimental
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369304/
https://www.ncbi.nlm.nih.gov/pubmed/34430945
http://dx.doi.org/10.1016/j.hroo.2021.06.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369304/
https://www.ncbi.nlm.nih.gov/pubmed/34430945
http://dx.doi.org/10.1016/j.hroo.2021.06.008

Ejemplares similares